Oncotelic Therapeutics, Inc. 8-K

What Happened

• On December 31, 2025, Oncotelic Therapeutics, Inc. filed an 8-K disclosing an amendment to its Independent Contractor Agreement with Jefferson Capital Ventures, LLC (original ICA dated August 6, 2025).
• The amendment changes the first milestone that would trigger restricted stock awards (RSAs) for Jefferson from the Company’s market capitalization exceeding $100 million on any single trading day’s close to $45 million on any single trading day’s close. No other terms of the milestone or ICA were changed.

Key Details

• Parties: Oncotelic Therapeutics, Inc. and Jefferson Capital Ventures, LLC.
• Amendment date: December 31, 2025; original ICA dated August 6, 2025.
• Milestone change: market-cap threshold lowered from $100 million to $45 million (measured by a single trading day’s close).
• Purpose stated by the company: to support continued progress including an equity line with Mast Hills, engagement of AGP for future financing, and engagement of Sichenzia, Ross & Ferrell for uplisting to a national exchange.
• The amendment and related form are filed as Exhibit 10.1 to the 8-K.

Why It Matters

• Lowering the milestone makes it easier for Jefferson to earn the RSAs, which could lead to future issuance of common stock and potential dilution for existing shareholders if the $45 million market-cap threshold is met.
• The change signals the company is pursuing financing and an uplisting strategy (equity line, finance engagement, counsel for uplisting), steps that could affect liquidity and visibility of the stock.
• Investors should watch future filings for any RSA issuances, updates on the equity line or financing engagements, and progress toward uplisting or achieving the revised market-cap milestone.